R7 (drug)

R7 (drug)
Clinical data
Routes of
administration		 Oral
Legal status
Legal status

R7 is a prodrug of 7,8-dihydroxyflavone (7,8-DHF) with significantly improved potency and pharmacokinetics (namely oral bioavailability) that is currently in preclinical development for the treatment of Alzheimer's disease.[1][2] As a prodrug of 7,8-DHF, R7 is a selective agonist of TrkB, the main receptor of brain-derived neurotrophic factor (BDNF).[1][2] 7,8-DHF shows robust efficacy in a variety of animal models of Alzheimer's disease as well as other conditions, making R7 a highly promising potential therapeutic agent.[1] The chemical structure of the compound has yet to be published.[1]

See also

References

  1. 1 2 3 4 Liu, Chaoyang; Chan, Chi Bun; Ye, Keqiang (2016). "7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders". Translational Neurodegeneration. 5 (1). doi:10.1186/s40035-015-0048-7. ISSN 2047-9158. PMC 4702337Freely accessible. PMID 26740873.
  2. 1 2 Kazim, Syed Faraz; Iqbal, Khalid (2016). "Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease". Molecular Neurodegeneration. 11 (1). doi:10.1186/s13024-016-0119-y. ISSN 1750-1326.



This article is issued from Wikipedia - version of the 12/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.